NCT04414163 2025-06-18A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeImmuneOncia Therapeutics Inc.Phase 2 Active not recruiting23 enrolled